Clinical and Translational Research
Copyright ©The Author(s) 2022.
World J Clin Cases. Jun 6, 2022; 10(16): 5165-5184
Published online Jun 6, 2022. doi: 10.12998/wjcc.v10.i16.5165
Figure 3
Figure 3 Evaluation of the diagnostic utility of serum miR-627-5p and miR-199a-5p in an independent cohort comprising 30 healthy controls, 60 advanced colorectal adenoma patients and 60 colorectal cancer patients. A: Identification of the serum expression levels of miR-627-5p and miR-199a-5p in healthy controls (HCs), advanced colorectal adenoma (AA) and colorectal cancer (CRC) patients by quantitative real-time polymerase chain reaction; B: Receiver operating characteristic (ROC) analysis of miR-627-5p to distinguish colorectal neoplasms from HCs. The areas under the curve (AUC) in discriminating CRC from HCs (blue line), AA from HCs (red line) and CRC+AA from HCs (black line) were 0.97, 0.84, and 0.90, respectively; C: ROC analysis of miR-199a-5p to distinguish colorectal neoplasms from HCs. The AUC in discriminating CRC from HCs (blue line), AA from HCs (red line) and CRC+AA from HCs (black line) were 0.90, 0.76, and 0.83, respectively; D: ROC analysis of the integrated biomarker panel (miR-627-5p level plus miR-199a-5p) to distinguish colorectal neoplasms from HCs. The AUC in discriminating CRC from HCs (blue line), AA from HCs (red line) and CRC+AA from HCs (black line) were 0.98, 0.86, and 0.92, respectively. cP < 0.001. HC: Healthy control; AA: Advanced colorectal adenoma; CRC: Colorectal cancer; AUC: Area under the curve.